---
title: "UCB Awards Annual Myasthenia Gravis Scholarships to 15 Individuals Impacted by MG in the U.S."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292075597.md"
description: "Today, in Atlanta, on July 8, 2026, UCB, a leading biopharmaceutical firm, unveiled the winners of its yearly UCB Myasthenia Gravis Scholarship. A total of 15 scholarships have been granted to recipients in the United States who are either personally affected by myasthenia gravis (MG) or are caregivers to those with the condition."
datetime: "2026-07-08T13:05:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292075597.md)
  - [en](https://longbridge.com/en/news/292075597.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292075597.md)
generator: "portal-rs"
---

# UCB Awards Annual Myasthenia Gravis Scholarships to 15 Individuals Impacted by MG in the U.S.

Today, in Atlanta, on July 8, 2026, UCB, a leading biopharmaceutical firm, unveiled the winners of its yearly UCB Myasthenia Gravis Scholarship. A total of 15 scholarships have been granted to recipients in the United States who are either personally affected by myasthenia gravis (MG) or are caregivers to those with the condition.

### Related Stocks

- [UCBJY.US](https://longbridge.com/en/quote/UCBJY.US.md)

## Related News & Research

- [Axios Names UCB a Winner of the Metro Atlanta Top Workplaces 2026 Award](https://longbridge.com/en/news/296023675.md)
- [UCB: Revenue and net sales grew over 20% YoY, with upgraded 2026 guidance and strong pipeline momentum](https://longbridge.com/en/news/294358362.md)
- [Moderna Just Doubled on a Massive Cancer Breakthrough. Here’s Why MRNA Stock Isn’t a Buy Yet.](https://longbridge.com/en/news/296643850.md)
- [iSpecimen ships hundreds of cancer blood specimens for international research order within three weeks](https://longbridge.com/en/news/296531044.md)
- [Moderna shares surge after it says its experimental mRNA cancer treatment passed a key test](https://longbridge.com/en/news/296382081.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**